Wendan Cheng

Dr. Wendan Cheng

The Second Hospital of Anhui Medical University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
PXPan Lin Xin
Pan Lin Xin
LJLi Fan Jie
Li Fan Jie
QCQian Cheng
Qian Cheng
JWJie Wang
Jie Wang
WCWendan Cheng
Wendan Cheng
It is well known that RA (Rheumatoid arthritis) is an autoimmune disease characterized by multiple and symmetric arthropathy. The main pathological features of RA are synovial hyperplasia, angiogenesis, pannus formation, inflammatory cell infiltration, articular cartilage, bone destruction, and ultimately joint dysfunction, even deformity. IL-35 (Interleukin-35) is a new member of the IL-12 (Interleukin-12) family, which is an immunosuppressive and anti-inflammatory cytokine secreted mainly by Treg (T regulatory cells). There is evidence suggested that IL-35 can attenuate the progression of RA through influencing the immune and pathological process. It suggests that IL-35 played an important role in the pathogenesis of RA, and can be used as a potential target for the future treatment of RA. This review summarizes the recent advances of IL-35 in the pathological roles and the therapeutic potential roles in RA.

6 July 2022 in Clinical Science
Verified
Journal Article
Open access
PDF file
XMXiao Ma
Xiao Ma
DCDechao Cai
Dechao Cai
YZYakun Zhu
Yakun Zhu
YZYao Zhao
Yao Zhao
XSXianbo Shang
Xianbo Shang
WCWendan Cheng
Wendan Cheng
Osteoarthritis (OA) is a heterogeneous condition characterised by cartilage degradation, subchondral sclerosis, and osteophyte formation, and accompanied by the generation of pro-inflammatory mediators and degradation of extracellular matrix. The current treatment for early OA is focused on the relief of symptoms, such as pain, but this treatment cannot delay the pathological process. L-Glutamine (L-Gln), which has anti-inflammatory and anti-apoptotic effects, is the most abundant amino acid in human blood. However, its role in OA has not been systematically studied. Therefore, the objective of this work was to explore the therapeutic effect and molecular mechanism of L-Gln on OA. In vitro, we found that L-Gln could upregulate the expression of the long non-coding RNA NKILA, which is regulated by the transforming growth factor-β1/SMAD2/3 pathway, and inhibit the activity of nuclear factor-κB, thereby decreasing the expression of nitric oxide synthase, cyclooxygenase-2, and matrix metalloproteinase-13 (MMP-13). This led to a reduction in the generation of nitrous oxide, prostaglandin E-2, tumour necrosis factor-α, and degradation of the extracellular matrix (i.e. aggrecan and collagen II) in rat OA chondrocytes. Moreover, intragastric administration of L-Gln reduced the degradation of cartilage tissue and expression of MMP-13 in a rat OA model. L-Gln also relieved the clinical symptoms in some patients with early knee joint OA. These findings highlight that L-Gln is a potential therapeutic drug to delay the occurrence and development of OA.

10 March 2017 in Nutrients
Verified
Journal Article
Open access
PDF file
WCWendan Cheng
Wendan Cheng
JJJuehua Jing
Juehua Jing
ZWZhen Wang
Zhen Wang
DWDongying Wu
Dongying Wu
YHYumin Huang
Yumin Huang
This study aimed to assess whether Ginsenoside Rg1 (Rg1) inhibits inflammatory responses in human chondrocytes and reduces articular cartilage damage in a rat model of osteoarthritis (OA). Gene expression and protein levels of type II collagen, aggrecan, matrix metalloproteinase (MMP)‐13 and cyclooxygenase‐2 (COX‐2) were determined in vitro by quantitative real‐time‐polymerase chain reaction and Western blotting. Prostaglandin E2 (PGE2) amounts in the culture medium were determined by enzyme‐linked immunosorbent assay (ELISA). For in vivo assessment, a rat model of OA was generated by anterior cruciate ligament transection (ACLT). Four weeks after ACLT, Rg1 (30 or 60 mg/kg) or saline was administered by gavage once a day for eight consecutive weeks. Joint damage was analyzed by histology and immunohistochemistry. Ginsenoside Rg1 inhibited Interleukin (IL)‐1β‐induced chondrocyte gene and protein expressions of MMP‐13, COX‐2 and PGE2, and prevented type II collagen and aggrecan degradation, in a dose‐dependent manner. Administration of Ginsenoside Rg1 to OA rats attenuated cartilage degeneration, and reduced type II collagen loss and MMP‐13 levels. These findings demonstrated that Ginsenoside Rg1 can inhibit inflammatory responses in human chondrocytes in vitro and reduce articular cartilage damage in vivo, confirming the potential therapeutic value of Ginsenoside Rg1 in OA.

31 October 2018 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
PDF file
ZLZiyu Li
Ziyu Li
FYFei Yao
Fei Yao
LCLi Cheng
Li Cheng
WCWendan Cheng
Wendan Cheng
LQLei Qi
Lei Qi
JJJuehua Jing
Juehua Jing

17 March 2020 in European Journal of Orthopaedic Surgery & Traumatology
Verified
Journal Article
Closed access
PDF file
HWHan Wu
Han Wu
WCWendan Cheng
Wendan Cheng
JJJuehua Jing
Juehua Jing

1 January 2021 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Open access
YLYanchang Liu
Yanchang Liu
ZTZhicheng Tong
Zhicheng Tong
CWChen Wang
Chen Wang
RXRunzhi Xia
Runzhi Xia
HLHuiwu Li
Huiwu Li
WCWendan Cheng
Wendan Cheng
Bone integration on the surface of titanium prosthesis is critical to the success of implant surgery. Good Bone integration at the contact interface is the basis of long-term stability. TiO2 nanotubes have become one of the most commonly used modification techniques for artificial joint prostheses and bone defect implants due to their good biocompatibility, mechanical properties and chemical stability. TiO2 nanotubes can promote F-actin polymerization in bone mesenchymal stem cells (BMSCs) and osteogenic differentiation. The possibility of F-actin as an upstream part to regulate GCN5 initiation of osteogenesis was discussed. The results of gene loss and functional acquisition assay, immunoblotting assay and fluorescence staining assay showed that TiO2 nanotubes could promote the differentiation of BMSCs into osteoblasts. The intervention of TiO2 nanotubes can make BMSCs form stronger F-actin fibre bundles, which can drive the differentiation process of osteogenesis. Our results showed that F-actin mediated nanotube-induced cell differentiation through promoting the expression of GCN5 and enhancing the function of GCN5 and GCN5 was a key regulator of the osteogenic differentiation of BMSCs induced by TiO2 nanotubes as a downstream mediated osteogenesis of F-actin, providing a novel insight into the study of osteogenic differentiation on surface of TiO2 nanotubes.